Immunologic effects of emdogain in humans: one-year results.
Tissue regeneration after therapeutic manipulations is essential in periodontology, oral surgery, and trauma of the periodontal tissues. Local inflammation because of poor oral hygiene also plays a crucial role in the above situations. Local inflammatory reaction, accompanied by the local production of cytokines, profoundly influences bone turnover and regeneration. Several products of low immunogenicity for augmenting tissue regeneration have been recently proposed as boosters of soft and mineralized tissue regeneration. Among them, Emdogain, an amelogenin derivative of porcine origin, has recently been introduced. Clinical results indicate that this product might be a good additive, producing fast tissue regeneration with no apparent clinical side effects. In contrast, very little is known about its in vivo immunologic effects. A previous study showed that Emdogain does not modify the cellular or humoral immune response in vitro. In the present work, performed in 10 patients, only a slight, nonsignificant activation of the immune system occurred during the first year following Emdogain application. Neither cellular immunity nor humoral immune response was significantly modified. In addition, the in vitro response of the patients' lymphocytes to Emdogain was assayed 2 and 12 months postoperative. We did not find any significant specific lymphocyte transformation in the presence of Emdogain, although lymphocytes could be stimulated by nonselective mitogens. These results indicate the immunologic safety of the agent in vivo, at least after 1 year.
Laboratory of Clinical Immunology, University of Crete, School of Medicine, University Hospital, Heraklion, Greece.
Symeon
S
Nikolopoulos
Efthymia
E
Peteinaki
Elias
E
Castanas
D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000601:surgery; D000704:Analysis of Variance; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D001861:Bone Regeneration / Q000187:drug effects*; D003746:Dental Enamel Proteins / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D007108:Immune Tolerance; D007111:Immunity, Cellular / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects; D013552:Swine
D003746:Dental Enamel Proteins; C109069:enamel matrix proteins